Biora Therapeutics, Inc. (BIOR)
NASDAQ: BIOR · IEX Real-Time Price · USD
0.713
+0.071 (11.03%)
At close: May 2, 2024, 4:00 PM
0.712
-0.001 (-0.11%)
After-hours: May 2, 2024, 7:51 PM EDT
Biora Therapeutics Revenue
In the year 2023, Biora Therapeutics had annual revenue of $4.00K, a decrease of -98.69%.
Revenue (ttm)
$4.00K
Revenue Growth
-98.69%
P/S Ratio
6,394.49
Revenue / Employee
$69
Employees
58
Market Cap
25.58M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.00K | -301.00K | -98.69% |
Dec 31, 2022 | 305.00K | -942.00K | -75.54% |
Dec 31, 2021 | 1.25M | 1.09M | 669.75% |
Dec 31, 2020 | 162.00K | -143.82M | -99.89% |
Dec 31, 2019 | 143.99M | 16.01M | 12.51% |
Dec 31, 2018 | 127.97M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Exagen | 52.55M |
Cumberland Pharmaceuticals | 39.55M |
Nephros | 14.24M |
Lumos Pharma | 2.05M |
Oncternal Therapeutics | 785.00K |
Bullfrog AI | 65.00K |
Lipocine | -2.85M |
BIOR News
- 2 days ago - Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600 - GlobeNewsWire
- 24 days ago - Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology - GlobeNewsWire
- 4 weeks ago - Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development - GlobeNewsWire
- 4 weeks ago - Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 weeks ago - Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 5 weeks ago - Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results - GlobeNewsWire
- 6 weeks ago - Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update - GlobeNewsWire
- 7 weeks ago - Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset - GlobeNewsWire